Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX)

CUSIP: 00430H102

Q1 2023 13F Holders as of 31 Mar 2023

Holder snapshot 7 signals
Share change
-1,031,682
Put/Call ratio
376%
SEC-reported price per share
$0.70
Number of holders
64
Value change
-$735,427
Number of buys
19
Open additional details 1 more signal available
Number of sells
27
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
27,795,576

Security key

00430H102

Report period

Q1 2023

Institutions

64

Top holders

10

Ownership snapshot

Top reported holders of AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
GRIFFIN ASSET MANAGEMENT,...
Disclosed value leader
GRIFFIN ASSET MANAGEMENT,...
Comparable rows
0/15
Latest evidence
13 Mar 2023
13F 3/4/5 Highest disclosed value: $6,050,238 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

GRIFFIN ASSET MANAGEMENT, INC. has the largest disclosed position value at $6.05M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens GRIFFIN ASSET MANAGEMENT, INC.'s linked filing trail.
Disclosed position value Top 5
GRIFFIN ASSET MANAGEMENT, INC. $6.05M
VANGUARD GROUP INC $2.02M
Birchview Capital, LP $1.59M
ORACLE INVESTMENT MANAGEMENT INC $1.15M
JPMORGAN CHASE & CO $1.03M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
GRIFFIN ASSET MANAGEMENT, INC.
13F
Company
13F
—
denominator unverified
$6,050,238
8,569,742 shares
— 31 Dec 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$2,018,488
2,859,049 shares
— 31 Dec 2022
Birchview Capital, LP
13F
Company
13F
—
denominator unverified
$1,590,000
2,252,388 shares
— 31 Dec 2022
ORACLE INVESTMENT MANAGEMENT INC
13F
Company
13F
—
denominator unverified
$1,149,422
1,628,077 shares
— 31 Dec 2022
JPMORGAN CHASE & CO
13F
Company
13F
—
denominator unverified
$1,029,000
1,457,455 shares
— 31 Dec 2022
Alyeska Investment Group, L.P.
13F
Company
13F
—
denominator unverified
$874,724
1,238,986 shares
— 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
64
Shares
24,494,123
Rows available
64
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders
64
Q1 2023 holders
64
Holder diff
0
Investor Q1 2023 Shares Q1 2023 Shares Share Diff Share Chg % Q1 2023 value Q1 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .